

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

	Financial		Non-financial		Non-personal	Date received by SIGN Executive	Date last updated or approved	Action	Approval signature and date
	Specific	Non-Specific	Specific	Non-Specific					
CHAIR									
Stuart Ralston	Arthritis Research UK, Professor of Rheumatology, Centre for Genomic and Experimental Medicine, University of Edinburgh, Western General Hospital, NHS Lothian (Honorary contract) – Research & teaching (UoE), Healthcare (NHS). I treat patients with osteoporosis. Consultancy – medical education (editor and chapter author of Davidson's Principles and Practice of	None	None	None	Novartis – Chair of a DMC on the use of Zoledronic acid in children with osteoporosis (lapsed 2017). Merck – Member of the DMC on the use of Odanacatib in osteoporosis (lapsed 2015). Amgen and UCB – investigator on a clinical trial with romosozumab. Eli Lilly – Chief investigator on a trial in	22.3.18	22.11.18 8.2.19 14.3.19 29.8.19	Chairing role only – no participation in considered judgement of key questions relating to key questions	

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

	<p>Medicine). I am a co-author of the rheumatology chapter which covers osteoporosis.</p> <p>Chair, Commission on Human Medicines – MHRA. The commission deals with licensing of products that are indicated for osteoporosis and bone disease.</p>				<p>osteoporosis imperfect in which Eli Lilly has donated Teriparatide.</p> <p>Eli Lilly – Sub-investigator on a clinical trial with Ixekizumab in patients with psoriatic arthritis.</p> <p>Abbvie – Was previously a local investigator on a clinical trial with Adalimumab in patients with psoriatic arthritis.</p> <p>Gilead – Sub-investigator on a clinical trial with 3 investigational medicinal products for Sjogren’s syndrome.</p>				
--	---	--	--	--	---	--	--	--	--

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

					<p>Pfizer – Was sub-investigator on a clinical trial with an investigational medicinal product for osteoarthritis.</p> <p>Novartis – Chief investigator on a clinical trial in patients at risk of Paget's disease in which Novartis donated the investigational medicinal product (Zoledronic acid).</p>				
GUIDELINE DEVELOPMENT GROUP MEMBER									
Jamie Fraser, General Practitioner	General Practitioner, Southside Road Surgery, 43 Southside Road, Inverness, IV2 4XA	None	None	None	Member of the CHM, as noted above this does involve licensing of products indicated in Osteoporosis	12.10.18	22.11.18 8.2.19 14.3.19 25.4.19	No action required	

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

							29.8.19		
Stephen Gallacher, Consultant Physician and Endocrinologist	<p>Consultant Physician and Endocrinologist, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF - NHS healthcare.</p> <p>SJ Gallacher (Medical) Ltd (until 31.12.18) – private medical practice.</p> <p>Lecture fees/advisory boards – Gilead (up to 3 per year). Internis (up to 2 per year). Amgen (none since 2017).</p> <p>Fees from UCB advisory board 12/2018.</p> <p>Travel sponsorship from Internis to attend</p>	None	Member of clinical and scientific committee of National Osteoporosis Society.	None	None	26.9.18	<p>22.11.18</p> <p>8.2.19</p> <p>14.3.19</p> <p>29.8.19</p>	No action required	

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

	meeting in Paris (April 2019)								
Phil Hannaford	Former General Practitioner and Epidemiologist, University of Aberdeen. Rm 1.025, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD. Education and research.	None	None	None	None	2.10.18	8.2.19 14.3.19 25.4.19	No action required	
Rosemary Hollick, Consultant Rheumatologist	Consultant Rheumatologist & Senior clinical Lecturer, Rheumatology, University of Aberdeen. Clinical & Research.	None	None	None	Committee Member Bone Research Society.	29.11.18	8.2.19 14.3.19 25.4.19 29.8.19		
Catherine McConnell, Patient Representative	None	None	None	None	None		22.11.18 14.3.19 25.4.19 29.8.19	No action required	

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

Gill Pullan, Patient Representative	Patient representative – Royal Osteoporosis Society members and volunteers committee member.	None	None	None	None	8.2.19	8.2.19 14.3.19 25.4.19	No action required	
Naomi Scott, Pharmacist	Pharmacist, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU. NHS Lothian.	None	None	None	None	27.9.18	8.2.19 25.4.19	No action required	
Rajeev Srivastava, Consultant Chemical Pathologist	Consultant Chemical Pathologist (Clinical Biochemist), Department of Clinical Biochemistry, Queen Elizabeth University Hospital, Govan Road, Glasgow. The Doctors Laboratory (Clinical Biochemistry	Nothing declared	Nothing declared	Nothing declared	Nothing declared	1.10.18	8.2.19 14.3.19 25.4.19	No action required	

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

	<p>laboratory at BMI Rosshall hospital in Glasgow) – Consultant Chemical Pathologist overseeing the Quality assurance and available for clinical and interpretive advice.</p> <p>Gave lecture to GPs on common biochemical problems including vitamin D deficiency – sponsored by Internis Pharmaceuticals Limited. Received remuneration from the company.</p>								
<p>Margaret Yates, Osteoporosis Specialist Nurse</p> <p>Nurse specialising in Rheumatology, NHS Lanarkshire.</p>	<p>Osteoporosis Specialist Nurse.</p>	Nothing declared	Nothing declared	Nothing declared	Nothing declared	22.10.18	<p>22.11.18</p> <p>8.2.19</p> <p>14.3.19</p> <p>25.4.19</p>	No action required	

REGISTER OF INTERESTS

SIGN guideline: Management of osteoporosis and the prevention of fragility fractures

29 August 2019

	Osteoporosis						29.8.19		
--	--------------	--	--	--	--	--	---------	--	--